Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1400
https://www.valueinhealthjournal.com/article/S1098-3015(18)31706-6/fulltext
Title :
Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31706-6&doi=10.1016/j.jval.2018.04.1400
First page :
Section Title :
Open access? :
No
Section Order :
648